Moderna, Inc.
https://www.modernatx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Moderna, Inc.
Nouscom Aims To Ride Neoantigen Cancer Vaccine Wave
Nouscom, with one major partner and strong confidence, is building research and manufacturing foundations to address significant market needs with its neoantigen cancer vaccine platform.
Vaccines In Brief: ACIP Recommends Valneva's Chikungunya Shot For Travelers, Lab Workers
CDC’s advisory committee also approves a VFC program update allowing for the rare, off-label use of tetanus toxoid- and diphtheria toxoid-containing vaccine in young children, and plans to move up timing of its COVID-19 vaccine recommendations for the 2024-2025 formulation.
COVID Vaccines: CDC Panel Says Older People ‘Should’ Get An Extra Dose
However, David Kaslow, director of the FDA’s vaccines office, says only a ‘may’ recommendation is supported and that giving an extra dose after June ‘may not be optimal’ if vaccines are reformulated for the fall.
Will Pfizer/BioNTech And Moderna Stay Atop The COVID-19 Vaccine Market Forever?
BIO CEO panelist Rajeev Venkayya argued that the huge amount of investment in COVID-19 vaccines makes it possible for new players to challenge Comirnaty and Spikevax’s dominance.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
-
Drug Discovery Technologies
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Caperna LLC
- Moderna Therapeutics, Inc.
- Moderna LLC
- Newco LS18, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice